Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.91 USD | +0.34% | -2.07% | -13.88% |
Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.88% | 4.58B | C+ | ||
+1.51% | 42.75B | B | ||
+49.22% | 41.61B | A | ||
+8.57% | 41.34B | B- | ||
-12.36% | 26.59B | C | ||
+8.92% | 25.49B | B- | ||
-25.13% | 18.12B | B | ||
+29.17% | 12.24B | C+ | ||
-3.12% | 11.76B | C+ | ||
+6.35% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CRSP Stock
- Ratings CRISPR Therapeutics AG